I have a significant (for my means) long position on MAKO and I have been following this board for the past few months. I have to confess that I am quite nervous about this investment because technology in medical sciences can be a very volatile factor.
Here are some positive points to take into consideration:
- There are some very favorable testimonials for the Makoplasty procedures.
- There are doctors that are committed to this kind of surgery and even use it in creative ways (maybe you have read about Mini Makoplasty and shoulder considerations have been mentioned quite a bit lately).
- The Makoplasty Facebook page has seen a surge of likes in the last week and almost all feedback is quite positive. Facebook pages of this type do not have too many likes but it would be interesting to draw a comparison with the corresponding page for Da Vinci.
- The Sunday Miami Herald article (which you can easily find through a google search) made a good case for Makoplasty and there are several similar articles showing up around the country.
- Some people might say that the competitors on today's list, posted by don, have better percentages but you have to remember that they have a much larger market footprint. All things considered these percentages are great for Mako.
Here are some negative points to take into consideration:
- The company burns a lot of cash and it can be anybody's guess when it will start making money.
- Top tier hospitals seem to still stay away from this technology. For example, I live in the Chicago area (norse we can meet up if you like) and this technology has not been adopted by U of C Hospitals or Northwestern Hospitals.
- International interest in Makoplasty still seems to be at a very early stage.
- The negative press on robotic surgery attributed to the Da Vinci is having a much wider effect that certainly includes Mako.
Any comments on the above points are quite welcome.
What;s odd is that last night, on the network news (in NYC), they ran a 60 second spot for the Oxford unicompartmental (Biomet), which pre-dated Mako. Never seen that before. Maybe they'll be some halo effect? Although, direct-to-patient in ortho has yet to work very well.
The DTC approach via tv ad will be interesting. Biomet and MAKO must both be pleased. Many hospitals/surgeons are locked into 2-3 yr cycles before review/renew and yet MAKO has performed over 20,000 unis pointing to expansion of the market which benefits both.
Sentiment: Strong Buy
I am afraid you are very wrong. The open interest for 12.50 puts is through the roof: 11,000 puts versus 2,000 calls for the same strike price. The picture for 10.00 strike price is equally bad: 700 calls vs 4000 puts. If you have any positive angle for this or think differently, I will be happy to hear your explanation/thinking.
Read his first paragraph its a give away. He's not in my opinion long. He's bringing doubt into those of us longs that believe the future is in front of the company.
That's why I came back. Tired of those that tell lies day in and day out to manipulate a stock.
The truth is that I am more invested in MAKO (so being long is just an understatement) than I would like to be and this is why I am so nervous. I envy your confidence and as I mentioned in my message I would be more than happy to meet in person with you. Good luck,
Starting to see inroads into the top tier hospitals but they definitely seemed to start with the community hospitals. HSS (#1 Ortho US News & World Report)) in NY has two units purchased in Nov 2011 after using a MAKO in research for a number of years, NYU Langone Medical Center, Mayo Clinic (at their Florida campus), Swedish Hospital in Seattle with 2 units (one at a satellite), Mercy Medical Center (Baltimore), USC Keck School of Medicine, Ohio State Univ Medical Center, Wake Forest, etc but so much room for improvement.
Sentiment: Strong Buy
we need a major deal with a major highly respected hospital mayo in minn,mass general ,brigham in mass etc.other major hospitals in europe and asia. places that other hospitals thru out this country respect and says this product is important to the medical community
donknute, of the latest batch of new hospitals, what percentage would you say is top tier vs. community? curious to know if Mako is picking up the pace with the top tier hospitals and while expansion is critical, are these the best targets for them at this stage?
Thanks for the great input. As stated in my post, I looked specifically at the Chicago area hospitals. Nevertheless the ones that you mention make a compelling case. Top tier hospitals will bring more international attention.